Although Enterococci are considered to be commensals and a normal part of the gut flora, they can also act as pathogens, and are becoming recognised as a significant cause of healthcare associated infection (HAI). According to the Health Protection Agency, Enterococcal bacteraemia is the the fourth most common type of bacteraemia seen in NHS hospitals, and is a particular problem in older patients and in the intensive care unit.
The vast majority of cases of Enterococcal bacteraemia can be linked to two causative pathogens, Enterococcus faecalis and Enterococcus faecium. However treatment decisions may be difficult as each species exhibits differing antibiotic resistance profiles.
While E. faecalis is generally susceptible to commonly prescribed antibiotics, infections with E. faecium, are frequently resistant and require a different therapy. The spread of these Glycopeptide resistant Enterococci(GRE) is a significant and growing problem. Since conventional identification methods can take up to 3 days or longer, patients with E.faecium bloodstream infections may receive inappropriate antimicrobial therapy for days leading to higher mortality and significant extra hospital costs.
Enterococcus QuickFISH allows clinicians to rapidly ensure early, appropriate therapy for patients with E. faecium infections, while minimising the unnecessary use of broad spectrum antibiotics
Please see Instructions for Use (IFU) for complete performance data.
1 In addition to 36 E. faecium, 3 E. gallinarum, and 1 E. raffinosus were identified in the clinical studies.
2 One false negative sample (tested 1 hour and 15 minutes from the time of Gram stain) was a mixed culture comprised of E. faecium, MRSA and K. pneumoniae. Repeat testing one week later was weak red-positive